Foscarnet eyedrops for the treatment of refractory herpetic keratitis.
Journal
Journal of ophthalmic inflammation and infection
ISSN: 1869-5760
Titre abrégé: J Ophthalmic Inflamm Infect
Pays: Germany
ID NLM: 101553216
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
14
07
2023
accepted:
29
03
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
23
10
2024
Statut:
epublish
Résumé
The purpose of this case series is to describe the clinical course of patients receiving foscarnet eyedrops for the treatment of refractory herpetic keratitis. Six patients diagnosed with herpetic keratitis were treated with foscarnet 24 mg/mL (2.4%) eyedrops with resulting improvement in keratitis. Topical foscarnet may be a safe and effective treatment for herpetic keratitis in conjunction with, or as an alternative to, conventional antiviral therapy. This is an off-label use of foscarnet.
Identifiants
pubmed: 39441228
doi: 10.1186/s12348-024-00395-0
pii: 10.1186/s12348-024-00395-0
doi:
Types de publication
Journal Article
Langues
eng
Pagination
54Informations de copyright
© 2024. The Author(s).
Références
White ML, Chodosh J, Center for Quality Eye Care and American Academy of Ophthalmology Website (2014) Herpes Simplex Virus Keratitis: A Treatment Guideline. Hoskins; https://www.aao.org/clinical-statement/herpes-simplex-virus-keratitis-treatment-guideline . Accessed January 16, 2022
van Velzen M, van de Vijver DA, van Loenen FB, Osterhaus AD, Remeijer L, Verjans GM (2013) Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis. J Infect Dis 208(9):1359–1365
doi: 10.1093/infdis/jit350
pubmed: 23901090
Liesegang TJ (2001) Herpes simplex virus epidemiology and ocular importance. Cornea 20:1–13
doi: 10.1097/00003226-200101000-00001
pubmed: 11188989
van Velzen M, van Loenen FB, Meesters RJ, de Graaf M, Remeijer L, Luider TM, Osterhaus AD, Verjans GM (2012) Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis 205(10):1539–1543
doi: 10.1093/infdis/jis237
pubmed: 22457282
Piret J, Boivin G (2016) Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Curr Opin Infect Dis 29(6):654–662
doi: 10.1097/QCO.0000000000000288
pubmed: 27306564
Choong K, Walker NJ, Apel AJ, Whitby M (2010) Aciclovir-resistant herpes keratitis. Clin Exp Ophthalmol 38(3):309–313
doi: 10.1111/j.1442-9071.2010.02209.x
pubmed: 20447128
Garikapati S, Nguyen M Foscarnet. [Updated 2021 Feb 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK556108/
Behrens-Baumann W (1992) Phosphonoformate (foscarnet, PFA) versus trifluorthymidine in the treatment of keratitis dendritica in the human. A double-blind, randomized, preliminary trial. Acta Ophthalmol (Copenh) 70(5):690–692
doi: 10.1111/j.1755-3768.1992.tb02154.x
pubmed: 1335203
Fabricius EM (1998) Foscarnet eyedrops in recurrence prophylaxis of herpes simplex virus keratitis. Acta Ophthalmol Scand 76(6):755–757 PMID: 9881570
Cao K (2001) Clinical research on treatment of herpes simplex keratitis with foscarnet sodium eye drops. Ophthalmol China [Yanke] 10(6):343–346
Yu J, Zhang M-C (2012) Clinical investigation of foscarnet sodium eye drops for the treatment of epithelial herpes simplex keratitis. Int Eye Sci 12(5):899–901
De Clerck I, Walgraeve V, Snoeck R, Andrei G, Blanckaert J, Mulliez E, Delbeke H (2022) Putting drug resistant epithelial herpes keratitis in the spotlight: a case series. Am J Ophthalmol Case Rep 25:101268
doi: 10.1016/j.ajoc.2022.101268
pubmed: 35112016
pmcid: 8790274
Pechère M, Wunderli W, Trellu-Toutous L, Harms M, Saura JH, Krischer J (1998) Treatment of acyclovir-resistant herpetic ulceration with topical foscarnet and antiviral sensitivity analysis. Dermatology 197(3):278–280
doi: 10.1159/000018014
pubmed: 9812037
Greeley ZW, Giannasca NJ, Porter MJ, Margulies BJ (2020) Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1. Antiviral Res 176:104754
doi: 10.1016/j.antiviral.2020.104754
pubmed: 32114034
Suzuki M, Okuda T, Shiraki K (2006) Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res 72(2):157–161
doi: 10.1016/j.antiviral.2006.05.001
pubmed: 16797734
Marcelletti JF (2002) Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs. Antiviral Res 56(2):153–166
doi: 10.1016/S0166-3542(02)00105-5
pubmed: 12367721
Aggarwal S, Cavalcanti BM, Pavan-Langston D (2014) Treatment of pseudodendrites in herpes zoster ophthalmicus with topical ganciclovir 0.15% gel. Cornea 33(2):109–113
doi: 10.1097/ICO.0000000000000020
pubmed: 24322809